Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
Laura Samples(University of Washington), Mazyar Shadman(University of Washington), Vikram Raghunathan(Seattle Cancer Care Alliance), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michael D. Jain(Moffitt Cancer Center), Peter A. Riedell(University of Chicago), Ryan C. Lynch(Seattle Cancer Care Alliance), Brian T. Hill(Cleveland Clinic), Lori A. Leslie(Hackensack University Medical Center), Jordan Gauthier(Seattle Cancer Care Alliance), Alan P Skarbnik(Novant Health), Mehdi Hamadani(Medical College of Wisconsin), Ariela Noy(Memorial Sloan Kettering Cancer Center), David G. Maloney(Fred Hutch Cancer Center), Saurabh Dahiya(Stanford University), Frederick L. Locke(Moffitt Cancer Center), Ted Gooley(Fred Hutch Cancer Center), Kikkeri N. Naresh(University of Washington), Roni Shouval(Memorial Sloan Kettering Cancer Center), Caron A. Jacobson(Dana-Farber Cancer Institute), Brian G. Till(University of Washington), Leyla Shune(University of Kansas Medical Center), Hossein Sadrzadeh(Boston University), Ashwath Gurumurthi(Medical University of South Carolina), Alexandre V. Hirayama(University of Washington), Monalisa Ghosh(Michigan Medicine), Valentín Ortiz‐Maldonado(Hospital Clínic de Barcelona), Paolo Strati(The University of Texas MD Anderson Cancer Center), Christina Poh(University of Washington), Matthew J. Frigault(Harvard University), Mengyang Di(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Núria Martínez‐Cibrián(Hospital Clínic de Barcelona), Chaitra S. Ujjani(Fred Hutch Cancer Center), Narendranath Epperla(University of Utah), Stephen D. Smith(Seattle Cancer Care Alliance), Jean A. Yared(University of Maryland, Baltimore), Mehrdad Shakib-Azar(Fred Hutch Cancer Center), Manali Kamdar(University of Colorado Cancer Center)
Cited by 15
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k